References
- Rostand SG, Kirk KA, Rutsky EA, et al. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med. 1982;306(21):1276–1279.
- Kasiske BL, Ramos EL, Gaston RS, et al. The evaluation of renal transplant candidates: clinical practice guidelines. Patient care and education committee of the american society of transplant physicians. J Am Soc Nephrol. 1995;6(1):1–34.
- Mauiyyedi S, Covlin RB. Pathology of kidney transplantation. In: Morris P, Knechtle SJ, editors. Kidney transplantation: principles and practice. 6th ed. Philadelphia: Elsevier; 2008. p. 398–430.
- Cemerski S, Shaw A. Immune synapses in T-cell activation. Curr Opin Immunol. 2006;18(3):298–304.
- Kirwan SE, Burshtyn DN. Regulation of natural killer cell activity. Curr Opin Immunol. 2007;19(1):46–54.
- Zhou W, Peng Q, Li K, et al. Role of dendritic cell synthesis of complement in the allospecific T cell response. Mol Immunol. 2007;44(1–3):57–63.
- Perkins BA, Ficociello LH, Roshan B, et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 2010;77(1):57–64.
- Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–232.
- Pena MJ, Jankowski J, Heinze G, et al. Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. J Hypertens. 2015;33(10):2123–2132.
- Ben Ameur R, Molina L, Bolvin C, et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant. 2010;25(9):2866–2875.
- Moresco RN, Sangoi MB, De Carvalho JA, et al. Diabetic nephropathy: traditional to proteomic markers. Clin Chim Acta. 2013;421:17–30.
- Heinzmann SS, Merrifield CA, Rezzi S, et al. Stability and robustness of human metabolic phenotypes in response to sequential food challenges. J Proteome Res. 2012;11(2):643–655.
- Caubet C, Lacroix C, Decramer S, et al. Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease. Pediatr Nephrol. 2010;25(1):27–35.
- Bishop P, Rocca D, Henley JM. Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction. Biochem J. 2016;473(16):2453–2462.
- Radón V, Czesla M, Reichelt J, et al. Ubiquitin C-terminal hydrolase L1 is required for regulated protein degradation through the ubiquitin proteasome system in kidney. Kidney Int. 2018;93(1):110–127.
- Kurian SM, Heilman R, Mondala TS, et al. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One. 2009;4(7):e6212.
- Mao Y, Yu J, Chen J, et al. Diagnosis of renal allograft subclinical rejection by urine protein fingerprint analysis. Transpl Immunol. 2008;18(3):255–259.